Manila Times Business
CervoMed Announces Private Placement Financing and Plan to Focus on Strategic Partnering to Advance Neflamapimod into Phase 3 for Dementia with Lewy Bodies
Additional funding will extend anticipated runway into second quarter of 2027 Strategic priority is to establish a partnership to advance neflamapimod into Phase 3 in dementia with Lewy bodies Anticipated pipeline milestones over next six months include obtaining 24-week biomarker and clinical data from Phase 2a trial evaluating neflamapimod in nonfluent variant primary progressive aphasia and initiation of EXPERTS-ALS Phase 2a trial Financing includes substantial participation from insiders and
This is an excerpt. Read the full article at the original source:
Source: manilatimes.net
Read Full Article on manilatimes.net →More from Manila Times Business
The ChariTree Foundation Calls for More Outdoor Learning Opportunities for Children in the Age of AI
Just now
Budweiser China Co-Hosts Global Night-Time Economy Dialogue in Shanghai, Highlighting Multinational Companies’ Role in Urban Consumption Growth
Just now
Completion of the Sale of the Share of Saare Kala Tootmine OÜ
Just now
Shufti Ranked as a Leader in G2’s Summer 2026 Identity Verification Grid® Report
Just now